Pre-funded warrants are a type of warrant where the holder pays most of the purchase price upfront, leaving only a nominal exercise price (typically $0.001 or $0.0001 per share). According to DilutionWatch data covering 7,300+ stocks, pre-funded warrants have become increasingly common in small-cap offerings since 2020, and they are functionally equivalent to common shares despite being classified as warrants.
Companies issue pre-funded warrants to investors who would exceed beneficial ownership thresholds (typically 4.99% or 9.99%) if they received common shares. The warrant structure allows investors to control the timing of beneficial ownership by holding warrants (which don't count toward ownership limits in most cases) and exercising them incrementally. The nominal exercise price means the warrants will always be exercised, making them guaranteed future dilution.
For dilution analysis, pre-funded warrants should be treated as outstanding shares because their exercise is virtually certain (no rational holder would forfeit shares available for $0.001). DilutionWatch includes pre-funded warrants in its fully diluted share count calculations and the DilutionScore™ algorithm. Companies that issue pre-funded warrants alongside common stock in an offering are typically conducting a larger capital raise than the common share count alone would suggest.
The key risk with pre-funded warrants is that the reported share count on a company's 10-Q cover page typically excludes pre-funded warrants, making the company appear less diluted than it actually is. Investors who only look at basic shares outstanding may significantly underestimate the true share count and therefore overestimate per-share metrics like EPS and book value per share.
DilutionWatch addresses this transparency gap by including pre-funded warrants in its adjusted share count and prominently flagging their existence on company risk pages. When evaluating a stock with pre-funded warrants, always add them to the outstanding share count for accurate per-share calculations. The footnotes to quarterly financial statements disclose pre-funded warrant quantities and terms.
Functionally yes. With exercise prices of $0.001 or less, pre-funded warrants will always be exercised. They should be treated as outstanding shares for valuation and dilution analysis. DilutionWatch includes them in fully diluted share counts.
Pre-funded warrants allow investors to participate in offerings without exceeding beneficial ownership thresholds (e.g., 4.99%). The warrant structure lets investors control when they appear as significant shareholders by timing their exercises.
Pre-funded warrants are disclosed in the equity footnotes of 10-Q and 10-K filings, and in the prospectus supplement for the offering in which they were issued. Look for warrants with exercise prices of $0.001 or $0.0001. DilutionWatch tracks these automatically.
DilutionWatch monitors 7,300+ stocks for dilution risk in real time. Get the DilutionScore™ for any ticker instantly.
Search DilutionWatch →